Acolbifene/prasterone

Drug Profile

Acolbifene/prasterone

Alternative Names: Femivia; Prasterone/Acolbifene

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endoceutics
  • Class Antineoplastics; Hormonal replacements; Osteoporosis therapies; Small molecules; Testosterone congeners
  • Mechanism of Action Cell differentiation stimulants; Immunomodulators; Selective estrogen receptor modulators; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Breast cancer; Osteoporosis; Vasomotor symptoms

Highest Development Phases

  • Phase III Decreased libido; Hypogonadism; Osteoporosis; Vasomotor symptoms
  • Discontinued Breast cancer

Most Recent Events

  • 17 Jan 2018 Phase-III development is ongoing for Vasomotor symptoms in Canada (Endoceutics pipeline, January 2018)
  • 17 Jan 2018 Discontinued for Breast cancer (Prevention) in Canada (PO) (Endoceutics pipeline, January 2018)
  • 17 Jan 2018 Phase-III clinical trials in Decreased libido in Canada (PO) (Endoceutics pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top